Carol O’Brien

4.2k total citations
31 papers, 2.4k citations indexed

About

Carol O’Brien is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Carol O’Brien has authored 31 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 8 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Carol O’Brien's work include PI3K/AKT/mTOR signaling in cancer (10 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Cancer Genomics and Diagnostics (5 papers). Carol O’Brien is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (10 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Cancer Genomics and Diagnostics (5 papers). Carol O’Brien collaborates with scholars based in United States, Ireland and France. Carol O’Brien's co-authors include Mark R. Lackner, Lukas C. Amler, Lori S. Friedman, Jill M. Spoerke, Marcia Belvin, Leanne Berry, Heidi Savage, Guy Cavet, Zachary Boyd and Howard M. Stern and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and NeuroImage.

In The Last Decade

Carol O’Brien

31 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carol O’Brien United States 19 1.7k 782 667 406 340 31 2.4k
Tracy Stockley Canada 24 905 0.5× 549 0.7× 781 1.2× 523 1.3× 481 1.4× 136 2.5k
Bruce W. Konicek United States 20 1.8k 1.1× 447 0.6× 344 0.5× 325 0.8× 203 0.6× 37 2.3k
Alex Lash United States 15 1.5k 0.9× 530 0.7× 295 0.4× 235 0.6× 324 1.0× 24 2.3k
Ranelle Salunga United States 13 1.5k 0.9× 910 1.2× 1.0k 1.5× 317 0.8× 320 0.9× 24 2.7k
Kurtis D. Davies United States 24 1.3k 0.7× 969 1.2× 509 0.8× 1.1k 2.6× 84 0.2× 51 2.9k
Chirayu Goswami United States 25 1.1k 0.6× 443 0.6× 572 0.9× 235 0.6× 154 0.5× 44 1.8k
Maud Kamal France 24 781 0.5× 499 0.6× 461 0.7× 306 0.8× 114 0.3× 87 1.7k
Robert Winqvist Finland 34 2.1k 1.2× 936 1.2× 853 1.3× 273 0.7× 1.1k 3.2× 89 3.3k
Sharon J. Diskin United States 29 1.9k 1.1× 678 0.9× 1.3k 2.0× 300 0.7× 787 2.3× 65 3.3k
Kirsten Vang Nielsen Denmark 26 808 0.5× 841 1.1× 516 0.8× 221 0.5× 322 0.9× 62 2.0k

Countries citing papers authored by Carol O’Brien

Since Specialization
Citations

This map shows the geographic impact of Carol O’Brien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carol O’Brien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carol O’Brien more than expected).

Fields of papers citing papers by Carol O’Brien

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carol O’Brien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carol O’Brien. The network helps show where Carol O’Brien may publish in the future.

Co-authorship network of co-authors of Carol O’Brien

This figure shows the co-authorship network connecting the top 25 collaborators of Carol O’Brien. A scholar is included among the top collaborators of Carol O’Brien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carol O’Brien. Carol O’Brien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Fan, et al.. (2025). P1337 High fat diet drives increased dysbiosis in IBD compared to healthy controls. Journal of Crohn s and Colitis. 19(Supplement_1). i2406–i2406. 1 indexed citations
2.
Ryan, Sinéad, Louise Crowe, Matthew D. Galbraith, et al.. (2024). Metabolic dysfunction mediated by HIF-1α contributes to epithelial differentiation defects in eosinophilic esophagitis. Journal of Allergy and Clinical Immunology. 154(6). 1472–1488. 2 indexed citations
3.
Nguyen, Giang Thi Tuyet, Carol O’Brien, Yessica Wouters, et al.. (2022). High-throughput proteomics and in vitro functional characterization of the 26 medically most important elapids and vipers from sub-Saharan Africa. GigaScience. 11. 22 indexed citations
4.
Veríssimo, Carolina De Marco, Carol O’Brien, Krystyna Cwiklinski, et al.. (2021). Improved diagnosis of SARS-CoV-2 by using nucleoprotein and spike protein fragment 2 in quantitative dual ELISA tests. Epidemiology and Infection. 149. e140–e140. 6 indexed citations
5.
Moore, Heather M., Heidi Savage, Carol O’Brien, et al.. (2019). Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models. Molecular Cancer Therapeutics. 19(1). 292–303. 8 indexed citations
6.
Nakanishi, Yoshito, Kimberly Walter, Jill M. Spoerke, et al.. (2016). Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β. Cancer Research. 76(5). 1193–1203. 55 indexed citations
7.
Savage, Heidi, Carol O’Brien, Heather M. Moore, et al.. (2016). Abstract 372: Taselisib enhances the potency of ERBB inhibitors in biomarker-defined subsets of head and neck squamous carcinoma cell lines. Cancer Research. 76(14_Supplement). 372–372. 1 indexed citations
8.
Wilson, Timothy R., Jianjun Yu, Xuyang Lu, et al.. (2016). The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population. npj Breast Cancer. 2(1). 16022–16022. 25 indexed citations
9.
Stern, Howard M., Humphrey Gardner, Tomasz Burzykowski, et al.. (2015). PTEN Loss Is Associated with Worse Outcome in HER2 -Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. Clinical Cancer Research. 21(9). 2065–2074. 57 indexed citations
10.
Schleifman, Erica, Rupal Desai, Jill M. Spoerke, et al.. (2014). Targeted Biomarker Profiling of Matched Primary and Metastatic Estrogen Receptor Positive Breast Cancers. PLoS ONE. 9(2). e88401–e88401. 30 indexed citations
11.
Kelly, Sinéad, Derek W. Morris, Omar Mothersill, et al.. (2014). Genome-wide schizophrenia variant at MIR137 does not impact white matter microstructure in healthy participants. Neuroscience Letters. 574. 6–10. 12 indexed citations
12.
Mothersill, Omar, Derek W. Morris, Sinéad Kelly, et al.. (2013). Effects of MIR137 on fronto-amygdala functional connectivity. NeuroImage. 90. 189–195. 39 indexed citations
13.
O’Brien, Carol, Ajay Pandita, Jill M. Spoerke, et al.. (2013). Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer. Oncogenesis. 2(12). e83–e83. 66 indexed citations
14.
Spoerke, Jill M., Carol O’Brien, Ling Huw, et al.. (2012). Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models. Clinical Cancer Research. 18(24). 6771–6783. 149 indexed citations
15.
Hatzivassiliou, Georgia, Bonnie Liu, Carol O’Brien, et al.. (2012). ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors. Molecular Cancer Therapeutics. 11(5). 1143–1154. 155 indexed citations
16.
Hoeflich, Klaus P., Carol O’Brien, Zachary Boyd, et al.. (2009). In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models. Clinical Cancer Research. 15(14). 4649–4664. 385 indexed citations
17.
Zha, Jiping, Carol O’Brien, Heidi Savage, et al.. (2009). Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Molecular Cancer Therapeutics. 8(8). 2110–2121. 66 indexed citations
18.
Hu, Xiaolan, Howard M. Stern, Lin Ge, et al.. (2009). Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes. Molecular Cancer Research. 7(4). 511–522. 177 indexed citations
19.
20.
Boyd, Zachary, Qun Wu, Carol O’Brien, et al.. (2008). Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays. Molecular Cancer Therapeutics. 7(12). 3695–3706. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tracy Stockley Breakdown of academic impact, for papers by Bruce W. Konicek Breakdown of academic impact, for papers by Alex Lash Breakdown of academic impact, for papers by Ranelle Salunga Breakdown of academic impact, for papers by Kurtis D. Davies Breakdown of academic impact, for papers by Chirayu Goswami Breakdown of academic impact, for papers by Maud Kamal Breakdown of academic impact, for papers by Robert Winqvist Breakdown of academic impact, for papers by Sharon J. Diskin Breakdown of academic impact, for papers by Kirsten Vang Nielsen
Rankless by CCL
2026